Phoenix Biotech Acquisition Corp.
PBAX
NASDAQ Global Market5.85
USD
+0.37
- -
CIK
0001870404
ISIN
US71902K1051
CUSIP
71902K105
Return %
Stock
S&P500
1Y
-45.22
18.21
3Y
-41.09
63.29
5Y
-41.09
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher B. Ehrlich
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2201 Broadway Oakland CA United States of America 94612
- IPO Date
- Nov 30, 2021
- CIK
- 0001870404
- Similar Companies
- Business
- Phoenix Biotech Acquisition Corp. was a special purpose acquisition company, established with the goal of identifying and combining with an operating business, particularly within the healthcare or related sectors across the United States and Europe. Incorporated in 2021 and headquartered in Oakland, California, the entity completed its business combination with CERo Therapeutics, Inc. in February 2024. Following the successful merger, Phoenix Biotech Acquisition Corp. transitioned into CERo Therapeutics Holdings, Inc., which now operates as an innovative immunotherapy company. The combined public company's shares are now listed on the Nasdaq Global Market under the ticker symbol CERO, focusing on advancing next-generation engineered T-cell therapeutics for oncology.
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination